-

Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company’s first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech innovators, policymakers, and regulators, with the goal of paving the way to the healthcare of the future - where the power of technology will be combined with the best of personalized care. She will lead the company’s global public policy, regulatory, and government affairs functions.

A former senior leader at the FDA, prosecutor for DOJ, and leader in the pharma industry and nonprofit sector, Deb Autor is a trusted visionary voice in health policy. She brings more than three decades of experience to help Hims & Hers ensure that innovation and integrity move hand in hand. Autor has played a key role in guiding Hims & Hers as a member of the Board of Directors since 2024.

“Extraordinary innovation in areas such as AI, robotics, and at-home diagnostics provides an opportunity to reshape how we deliver access to healthcare,” said Deb Autor, Chief Policy Officer at Hims & Hers. “Now is the time to harness new technologies to make care more proactive, personal, and accessible. Hims & Hers is setting a new standard for what responsible progress in healthcare looks like, and I’m excited to help shape the policies that will make that future a reality.”

Autor previously served as Deputy Commissioner for Global Regulatory Operations and Policy at the FDA, where she directed worldwide inspections, enforcement, and international engagement efforts. Earlier in her career, she led enforcement and policymaking for drug requirements at the FDA’s Office of Compliance for the Center for Drug Evaluation and Research, and represented the FDA as a trial attorney for the U.S. Department of Justice. More recently in the private sector, Autor’s roles include Global Head of Regulatory Excellence at AstraZeneca and CEO of Healthcare Innovation Catalysts.

“As digital health continues to evolve, the policies we shape today will define access, safety, and innovation for years to come,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “Deb’s unparalleled regulatory experience and forward-looking vision make her the ideal leader to guide our engagement with stakeholders at this pivotal moment.”

Autor’s appointment marks a significant milestone in Hims & Hers’ evolution as the company continues to scale its engagement with regulators and policymakers. Her leadership will guide the company’s efforts to shape a modern regulatory framework that combines innovation with accountability, ensuring consumers can confidently access safe, effective, and trusted care online. Autor will also continue to serve as a member of the Hims & Hers Board of Directors.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

Contacts

Javier Lacayo
press@forhims.com

Hims & Hers

NYSE:HIMS

Release Versions

Contacts

Javier Lacayo
press@forhims.com

More News From Hims & Hers

Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Wegovy®**. This needle-free treatment joins a full suite of weight loss solutions designed to meet the specific needs and preferences of individual customers. By leveraging nearly a decade of infrastructur...

Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care

SAN FRANCISCO--(BUSINESS WIRE)--Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a simple cancer screening blood test that can detect a signal for 50+ types of cancer even before symptoms appear1. This multi-cancer early detection (MCED) test combines Hims & Hers’ scale with GRAIL’s innovative cancer screening technology to dramatically increase access to proactive care....

Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international pa...
Back to Newsroom